肺大细胞神经内分泌癌的综合治疗策略  

The comprehensive treatment strategy of large cell neuroendocrine lung cancer

作　　者：杜奕佳 韩德前 喻杨[1] 张立搏(综述) 黄媚娟(审校)[1] DU Yijia;HAN Deqian;YU Yang;ZHANG Libo(reviewing);HUANG Meijuan(checking)(Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology,Cancer Center,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Oncology,West China School of Public Health and West China Fourth Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院肿瘤中心胸部肿瘤病房,四川成都610041 [2]四川大学华西公共卫生学院·华西第四医院肿瘤科,四川成都610041

出　　处：《西部医学》2024年第8期1242-1248,共7页Medical Journal of West China

基　　金：四川大学华西医院临床研究孵化项目重点项目(2021H XFH055)。

摘　　要：肺大细胞神经内分泌癌(LCNEC)是一种相对罕见的肺癌亚型,诊断困难,预后差。目前LCNEC的治疗大多参照小细胞肺癌(SCLC)或非小细胞肺癌(NSCLC)方案执行,并且免疫检查点抑制剂(ICIs)在LCNEC治疗中的疗效尚不明确。本文将对近年来LCNEC的化疗、免疫治疗、靶向治疗、放疗等方面的研究进展予以综述。Lung large cell neuroendocrine carcinoma(LCNEC)is a rare subtype of lung cancer with a poor prognosis and difficult to diagnose.There is currently no standard chemotherapy for LCNEC,the treatment option is mostly based on small cell lung cancer(SCLC)or non small cell lung cancer(NSCLC)regimens and the efficacy of ICIs of LCNEC is poorly characterized.Here,recent treatment progress in LCNEC,including chemotherapy,immunotherapy,targeted therapyandradiotherapy is reviewed.

关 键 词：LCNEC 化疗 靶向治疗 免疫治疗 放疗 

分 类 号：R734.2[医药卫生—肿瘤]